1629586-23-7

Basic information

• Product Name: tert-butyl ((3S,4S)-4-aminotetrahydrofuran-3-yl)carbamate
• CAS NO: 1629586-23-7
• Molecular Weight: 202.254
• Mol File: 1629586-23-7.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: tert-butyl ((3S,4S)-4-aminotetrahydrofuran-3-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl ((3S,4S)-4-aminotetrahydrofuran-3-yl)carbamate(1629586-23-7)
• EPA Substance Registry System: tert-butyl ((3S,4S)-4-aminotetrahydrofuran-3-yl)carbamate(1629586-23-7)

Safety Data

• Hazardous Substances Data: 1629586-23-7(Hazardous Substances Data)

Upstream product

• 45434-73-9 (3S,4S)-tetrahydro-3,4-furandiamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1160187-62-1 tert-butyl ((3R,4R)-4-hydroxytetrahydrofuran-3-yl)carbamate 
• 1430230-65-1 (±)-trans-3-tert-butoxycarbonylamino-4-hydroxytetrahydrofuran 
• 137277-16-8 (3R,4S)-tetrahydrofuran-3,4-diamine dihydrochloride 
• 1430230-65-1 tert-butyl ((3S,4R)-4-hydroxytetrahydrofuran-3-yl)carbamate 
• 1430230-65-1 (3R,4S)-3-tert-butoxycarbonylamino-4-hydroxytetrahydrofuran 

Relevant articles and documents

SALT FORM AND CRYSTAL FORM OF COMPOUND AS FGFR4 INHIBITOR AND PREPARATION METHOD THEREOF

The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR

Disclosed are heterocyclic compounds as inhibitors of FGFR-4 represented by formula (I). Also disclosed is a pharmaceutical composition that includes an inhibitor of FGFR-4. The compounds maybe used to treat diseases mediated with abnormality of FGFR-4 and /or FGF19, such as hepatocellular carcinoma and other forms of cancer.

FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.